Unit:
Library of the School of Health SciencesΠΜΣ Ογκολογία Θώρακα: Σύγχρονη Κλινικο-Εργαστηριακή Προσέγγιση και Έρευνα
Supervisors info:
Ροβίνα Νικολέττα, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ, Επιβλέπουσα
Ταβερναράκη Κυριακή, Ακτινολόγος, Επιμελήτρια Α’, Τμήμα Ιατρικής Απεικόνισης και Επεμβατικής Ακτινολογίας, ΓΝΝΘΑ «Η Σωτηρία»
Χαρπίδου Ανδριανή, Επιστημονική Συνεργάτης, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Εκτίμηση iRECIST κριτηρίων σε ασθενείς με καρκίνο πνεύμονα. Η εμπειρία ενός κέντρου.
Translated title:
Evaluation of iRECIST criteria in patients with lung cancer. The experience of a center.
Summary:
Part of the most significant and fundamental developments in the modern oncology world are therapeutic agents that act by targeting the human immune system. These are proving to be extremely beneficial and effective in various types of malignant diseases including lung cancer. One of the first malignancies in which a shift in the therapeutic approach using immunotherapy was recognized, compared to conventional cytotoxic therapies, is non-small cell lung cancer (NSCLC). With the use of immunotherapy, different patterns of therapeutic response have been identified. The identification and proper evaluation of these are challenging for both the clinician and the radiologist, as they differ significantly from those of common cytotoxic therapies. Therefore, the generally used criteria, such as the WHO (World Health Organization) and RECIST (Response Evaluation Criteria in Solid Tumours), become insufficient for the evaluation of the therapeutic response of patients under immunotherapy and, consequently, the assessment of their disease progression. By evaluating the therapeutic response in patients under immunotherapy, criteria have been studied and proposed, such as irRC (immune-related response criteria) and irRECIST (immune-related RECIST) which are applied at the level of clinical trials, with satisfactory results. In 2017, the iRECIST (immune RECIST) criteria were published to provide a more accurate and efficient assessment of the therapeutic effect in patients receiving immunotherapy. In this thesis, a total of 30 patients with non-small cell lung cancer (NSCLC) from the 3rd Pathological University Clinic of the General Hospital «Sotiria» were studied. The patients had received immunotherapy either as a first-line treatment or during the progression of the disease. The therapeutic effect was further assessed based on the iRECIST criteria. The aim of this research is to analyze and determine the way to assess the therapeutic response of patients under immunotherapy, based on the newest radiological imaging criteria. The consideration and appropriate application of these innovative criteria are of major importance at the level of clinical trials and in daily application.
Main subject category:
Health Sciences
Keywords:
iRECIST, NSCLC, Immunotherapy
File:
File access is restricted only to the intranet of UoA.
MSc ΔΗΜΗΤΡΟΥΛΗ Σ. ΦΑΝΗ.pdf
4 MB
File access is restricted only to the intranet of UoA.
